Starpharma (ASX:SPL) share price tanks 3% on 67% revenue drop

Starpharma shares are taking today…

| More on:
share price dropping

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price has dropped 2.76% this Thursday as the pharmaceutical company reported its earnings for the financial year ended 30 June 2021 (FY2021).

Starpharma share price slumps as revenues fall, losses mount

  • Revenues from continuing operations of $2.15 million, down 67% compared to the prior corresponding period of FY2020 (pcp)
  • Total revenues and other income of $3.5 million, down 50.7% from pcp
  • Loss after tax of $19.73 million, an increase of 34% over the pcp's loss of $14.7 million
  • No final dividend was declared for FY2021

What happened in FY21 for Starpharma?

The financial year just passed was a wild one for Starpharma, as evidenced by the company's share price range over the past year. With a 52-week high of $2.51 a share and a low of $1.12, investors have certainly been erratic at valuing this company's shares.

Back in February, investors lit a rocket under Starpharma shares when it announced that its Viraleze nasal spray, which has antiviral applications, gained successful registration for sale in Europe. That included the United Kingdom (UK). This news seemed to be the driving force behind Starpharma reaching its new all-time high in February. However, since then, the road has been rockier.

In June, the company took a bit of a hit. The UK Medicines and Healthcare Products Regulatory Agency pinged Starpharma for "allowable promotional claims" promoting Viraleze as a potential preventative measure against COVID-19 infection. The Starpharma share price fell around 10% at the time.

However, last month, the shares once again got a boost when Starpharma announced that Viraleze "has potent virucidal activity against the Delta variant of COVID-19".

What did management say?

Here's some of what Starpharma CEO Dr Jackie Fairley had to say on Starpharma's FY21 numbers today:

2021 has been a remarkable year for all of us around the world. Despite the impact of the unrelenting global pandemic, Starpharma was able to continue to recruit into our three DEP phase 2 clinical programs and achieve a number of important commercial milestones across the business. These included the rapid development and launch of VIRALEZE… 

The company is extremely proud to have developed, registered and launched VIRALEZE ahead of schedule and in time for it to play a role in the evolving situation in Europe.

What's next for Starpharma?

Dr Fairley also stated that the year ahead will see Starpharma focus on its DEP drug delivery platform. As well as  progressing "further registrations, distribution arrangements and launches for VIRALEZE in other regions". It will also aim for further registrations and launches of its VivaGel product.

Although the Starpharma share price is down more than 3% today, the company's losses for 2021 so far are now sitting at 19.8% year to date. The company is also down around 7.15% over the past 12 months. At the current Starpharma share price of $1.24, the company has a market capitalisation of $501.51 million.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

Up 74% in 2024, why is this ASX 200 stock rallying today?

Recurring revenues continue to grow.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

Guess which ASX All Ords share is soaring on 21% FY 2024 growth

Investors are piling into the ASX All Ords share today. Let’s find out why.

Read more »

Girl sliding down on snow with arms spread out.
Earnings Results

Elders shares on ice for a $475 million acquisition after profits plunge 55%

What on earth is going on with Elders shares today?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Energy Shares

This ASX 200 mining stock just reported a 40% earnings jump

Investors appear pleased with this miner's performance during the first quarter.

Read more »

Business people discussing project on digital tablet.
Earnings Results

2 ASX All Ords shares surging over 10% on strong results

Investors are buying these shares in response to strong results this morning.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Earnings Results

Xero share price rockets to record high on explosive half-year growth

The tech star delivered another impressive half year results this morning.

Read more »

A man cheers after winning computer game while woman sitting next to him looks upset.
Earnings Results

2 high-flying ASX 200 gaming shares splitting ways today

Which gaming giant is winning the admiration of investors amid results?

Read more »

Male building supervisor wearing high vis vest and hard hat stands and smiles with his arms crossed at a building site
Industrials Shares

This $23 billion ASX 200 stock is surging 6% while the market sinks. Here's why

This ASX 200 stock is shrugging off the wider market sell down today and racing higher. But why?

Read more »